Report cover image

Data Center Physical Infrastructure Market Size, Share, Trends, & Industry Analysis Report By Component (Cabling, Power Systems, Cooling Systems, Cable Management Solutions, Cabinets, and Others), By Deployment, By End User, and By Region – Market Forecas

Published Sep 01, 2025
Length 128 Pages
SKU # PLRS20451554

Description

The data center physical infrastructure market size is expected to reach USD 127.15 billion by 2034, according to a new study by Polaris Market Research. The report “Data Center Physical Infrastructure Market Share, Size, Trends, Industry Analysis Report: By Component (Cabling, Power Systems, Cooling Systems, Cable Management Solutions, Cabinets, and Others), By Deployment, By End User, and By Region; Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Components such as power supply units, cooling systems, racks, cabling, fire suppression, and security systems come under data center physical infrastructure. These systems ensure that servers and networking equipment function properly. Organizations rely on this infrastructure to protect sensitive information and deliver fast digital services.

Businesses in banking, healthcare, retail, and technology need data center physical infrastructure to process large volumes of data securely. Companies are investing in physical infrastructure with the growing cloud computing, big data, and AI continue to grow. Data center physical infrastructure ensures that data centers handle rising workloads, reduce operational costs, and support future technological innovations.

Data Center Physical Infrastructure Market Report Highlights

In terms of component, the power systems segment accounted for a major revenue share in 2024. This is due to the growth of data analytics and big data analytics, as well as the expansion of e-commerce.

Based on deployment, the on-premises segment held the largest revenue share in 2024. This is owing to on-premises ability to offer greater control, security, and customization.

In terms of end user, the IT and telecom segment dominated the revenue share in 2024. This is due to the rapid expansion of 5G networks, cloud platforms, and streaming services.

The healthcare segment is estimated to grow at a rapid CAGR from 2025 to 2034. This is due to high adoption of digital health solutions, telemedicine, and precision medicine.

North America accounted for a major data center physical infrastructure market share in 2024. This is attributed to high cloud adoption and digital transformation.

U.S. held the largest revenue share in the North America data center physical infrastructure landscape in 2024. This is due to the migration of businesses to the cloud and the digitalization of services such as healthcare and public services.

The Asia Pacific market is projected to hold a significant revenue share in 2034, driven by e-commerce expansion.

The demand for data center physical infrastructure in China is being driven by massive investments in AI research, cloud services, and e-commerce platforms.

The industry in Europe is projected to grow at a rapid CAGR from 2025 to 2034, owing to strict data sovereignty laws, growth of cloud services, and the shift toward digital business models.

A few global key market players include ABB; CoreSite; Dell; Digital Realty; Eaton; Equinix; Hewlett Packard Enterprise (HPE); IBM; Schneider Electric; Switch, Inc.; and Vertiv.

Polaris Market Research has segmented the market report on the basis of component, deployment, end user, and region:

By Component Outlook (Revenue, USD Billion, 2020–2034)

Cabling

Power Systems

Cooling Systems

Cable Management Solutions

Cabinets

Others

By Deployment Outlook (Revenue, USD Billion, 2020–2034)

On-Premises

Cloud-Based

By End User Outlook (Revenue, USD Billion, 2020–2034)

IT and Telecom

BFSI

Healthcare

Retail

Government and Defense

Others

By Regional Outlook (Revenue, USD Billion, 2020–2034)

North America

US

Canada

Europe

Germany

France

UK

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

South Korea

Indonesia

Australia

Vietnam

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa

Rest of Middle East & Africa

Latin America

Mexico

Brazil

Argentina

Rest of Latin America

Table of Contents

128 Pages
1. Introduction
1.1. Report Description
1.1.1. Objectives of the Study
1.1.2. Market Scope
1.1.3. Assumptions
1.2. Stakeholders
2. Executive Summary
2.1. Market Highlights
3. Research Methodology
3.1. Overview
3.1.1. Data Mining
3.2. Data Sources
3.2.1. Primary Sources
3.2.2. Secondary Sources
4. U.S. Point-of-Care (PoC) diagnostics Market Insights
4.1. U.S. Point-of-Care (PoC) diagnostics Market – Market Snapshot
4.2. U.S. Point-of-Care (PoC) diagnostics Market Dynamics
4.2.1. Drivers and Opportunities
4.2.1.1. Growing Prevalence of Chronic Diseases
4.2.1.2. Rising Advancement in PoC Technology
4.2.2. Restraints and Challenges
4.2.2.1. High procedure costs
4.2.3. Public opinion and privacy legal precedents
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers (Moderate)
4.3.2. Threats of New Entrants: (Low)
4.3.3. Bargaining Power of Buyers (Moderate)
4.3.4. Threat of Substitute (Moderate)
4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. U.S. Point-of-Care (PoC) diagnostics Market Trends
4.6. Value Chain Analysis
5. U.S. Point-of-Care (PoC) diagnostics Market, By Product
5.1. Key Findings
5.2. Introduction
5.2.1. U.S. Point-of-Care (PoC) diagnostics Market, By Product, by Region, 2020–2034 (USD Billion)
5.3. Glucose Testing
5.3.1. U.S. Point-of-Care (PoC) diagnostics Market, by Glucose Testing, by Region, 2020–2034 (USD Billion)
5.4. Hb1Ac Testing
5.4.1. U.S. Point-of-Care (PoC) diagnostics Market, by Hb1Ac Testing, by Region, 2020–2034 (USD Billion)
5.5. Coagulation
5.5.1. U.S. Point-of-Care (PoC) diagnostics Market, by Coagulation, by Region, 2020–2034 (USD Billion)
5.6. Fertility
5.6.1. U.S. Point-of-Care (PoC) diagnostics Market, by Fertility, by Region, 2020–2034 (USD Billion)
5.7. Infectious Diseases
5.7.1. U.S. Point-of-Care (PoC) diagnostics Market, by Infectious Diseases, by Region, 2020–2034 (USD Billion)
5.7.2. HIV
5.7.2.1. U.S. Point-of-Care (PoC) diagnostics Market, by HIV, by Region, 2020–2034 (USD Billion)
5.7.3. Clostridium Difficile
5.7.3.1. U.S. Point-of-Care (PoC) diagnostics Market, by Clostridium Difficile, by Region, 2020–2034 (USD Billion)
5.7.4. HBV
5.7.4.1. U.S. Point-of-Care (PoC) diagnostics Market, by HBV, by Region, 2020–2034 (USD Billion)
5.7.5. Pneumonia or Streptococcus Associated Infections
5.7.5.1. U.S. Point-of-Care (PoC) diagnostics Market, by Pneumonia or Streptococcus Associated Infections, by Region, 2020–2034 (USD Billion)
5.7.6. Respiratory Syncytial Virus (RSV)
5.7.6.1. U.S. Point-of-Care (PoC) diagnostics Market, by Respiratory Syncytial Virus (RSV), by Region, 2020–2034 (USD Billion)
5.7.7. HPV
5.7.7.1. U.S. Point-of-Care (PoC) diagnostics Market, by HPV, by Region, 2020–2034 (USD Billion)
5.7.8. Influenza/Flu
5.7.8.1. U.S. Point-of-Care (PoC) diagnostics Market, by Influenza/Flu, by Region, 2020–2034 (USD Billion)
5.7.9. HCV
5.7.9.1. U.S. Point-of-Care (PoC) diagnostics Market, by HCV, by Region, 2020–2034 (USD Billion)
5.7.10. MRSA
5.7.10.1. U.S. Point-of-Care (PoC) diagnostics Market, by MRSA, by Region, 2020–2034 (USD Billion)
5.7.11. TB and Drug-Resistant TB
5.7.11.1. U.S. Point-of-Care (PoC) diagnostics Market, by TB and Drug-Resistant TB, by Region, 2020–2034 (USD Billion)
5.7.12. HSV
5.7.12.1. U.S. Point-of-Care (PoC) diagnostics Market, by HSV, by Region, 2020–2034 (USD Billion)
5.7.13. Others
5.7.13.1. U.S. Point-of-Care (PoC) diagnostics Market, by Others, by Region, 2020–2034 (USD Billion)
5.8. Cardiac Markers
5.8.1. U.S. Point-of-Care (PoC) diagnostics Market, by Cardiac Markers, by Region, 2020–2034 (USD Billion)
5.9. Thyroid Stimulating Hormone
5.9.1. U.S. Point-of-Care (PoC) diagnostics Market, by Thyroid Stimulating Hormone, by Region, 2020–2034 (USD Billion)
5.10. Hematology
5.10.1. U.S. Point-of-Care (PoC) diagnostics Market, by Hematology, by Region, 2020–2034 (USD Billion)
5.11. Primary Care Systems
5.11.1. U.S. Point-of-Care (PoC) diagnostics Market, by Primary Care Systems, by Region, 2020–2034 (USD Billion)
5.12. Decentralized Clinical Chemistry
5.12.1. U.S. Point-of-Care (PoC) diagnostics Market, by Decentralized Clinical Chemistry, by Region, 2020–2034 (USD Billion)
5.13. Feces
5.13.1. U.S. Point-of-Care (PoC) diagnostics Market, by Feces, by Region, 2020–2034 (USD Billion)
5.14. Lipid Testing
5.14.1. U.S. Point-of-Care (PoC) diagnostics Market, by Lipid Testin, by Region, 2020–2034 (USD Billion)
5.15. Cancer Marker
5.15.1. U.S. Point-of-Care (PoC) diagnostics Market, by Cancer Marker, by Region, 2020–2034 (USD Billion)
5.16. Blood Gas/Electrolytes
5.16.1. U.S. Point-of-Care (PoC) diagnostics Market, by Blood Gas/Electrolytes, by Region, 2020–2034 (USD Billion)
5.17. Ambulatory Chemistry
5.17.1. U.S. Point-of-Care (PoC) diagnostics Market, by Ambulatory Chemistry, by Region, 2020–2034 (USD Billion)
5.18. Drug Abuse Testing
5.18.1. U.S. Point-of-Care (PoC) diagnostics Market, by Drug Abuse Testing, by Region, 2020–2034 (USD Billion)
5.19. Urinalysis
5.19.1. U.S. Point-of-Care (PoC) diagnostics Market, by Urinalysis, by Region, 2020–2034 (USD Billion)
6. U.S. Point-of-Care (PoC) diagnostics Market, By Mode of Prescription
6.1. Key Findings
6.2. Introduction
6.2.1. U.S. Point-of-Care (PoC) diagnostics Market, By Mode of Prescription, by Region, 2020–2034 (USD Billion)
6.3. OTC
6.3.1. U.S. Point-of-Care (PoC) diagnostics Market, by OTC, by Region, 2020–2034 (USD Billion)
6.4. Prescription-based
6.4.1. U.S. Point-of-Care (PoC) diagnostics Market, by Prescription-based, by Region, 2020–2034 (USD Billion)
7. U.S. Point-of-Care (PoC) diagnostics Market, By End Use
7.1. Key Findings
7.2. Introduction
7.2.1. U.S. Point-of-Care (PoC) diagnostics Market, By End Use, by Region, 2020–2034 (USD Billion)
7.3. Clinics
7.3.1. U.S. Point-of-Care (PoC) diagnostics Market, by Clinics, by Region, 2020–2034 (USD Billion)
7.3.2. Physician Office
7.3.2.1. U.S. Point-of-Care (PoC) diagnostics Market, by Physician Office, by Region, 2020–2034 (USD Billion)
7.3.3. Pharmacy & Retail Clinics
7.3.3.1. U.S. Point-of-Care (PoC) diagnostics Market, by Pharmacy & Retail Clinics, by Region, 2020–2034 (USD Billion)
7.3.4. Non-practice Clinics
7.3.4.1. U.S. Point-of-Care (PoC) diagnostics Market, by Non-practice Clinics, by Region, 2020–2034 (USD Billion)
7.3.5. Urgent Care Clinic
7.3.5.1. U.S. Point-of-Care (PoC) diagnostics Market, by Urgent Care Clinic, by Region, 2020–2034 (USD Billion)
7.4. Hospitals
7.4.1. U.S. Point-of-Care (PoC) diagnostics Market, by Hospitals, by Region, 2020–2034 (USD Billion)
7.5. Home
7.5.1. U.S. Point-of-Care (PoC) diagnostics Market, by Home, by Region, 2020–2034 (USD Billion)
7.6. Assisted Living Healthcare Facilities
7.6.1. U.S. Point-of-Care (PoC) diagnostics Market, by Assisted Living Healthcare Facilities, by Region, 2020–2034 (USD Billion)
7.7. Laboratory
7.7.1. U.S. Point-of-Care (PoC) diagnostics Market, by Laboratory, by Region, 2020–2034 (USD Billion)
8. Competitive Landscape
8.1. Expansion and Acquisition Analysis
8.1.1. Expansion
8.1.2. Acquisitions
8.2. Partnerships/Collaborations/Agreements/Exhibitions
9. Company Profiles
9.1. Abbott
9.1.1. Company Overview
9.1.2. Financial Performance
9.1.3. Product Benchmarking
9.1.4. Recent Development
9.2. Agilent Technologies, Inc.
9.2.1. Company Overview
9.2.2. Financial Performance
9.2.3. Product Benchmarking
9.2.4. Recent Development
9.3. BD
9.3.1. Company Overview
9.3.2. Financial Performance
9.3.3. Product Benchmarking
9.3.4. Recent Development
9.4. BIOMÉRIEUX
9.4.1. Company Overview
9.4.2. Financial Performance
9.4.3. Product Benchmarking
9.4.4. Recent Development
9.5. Danaher Corporation
9.5.1. Company Overview
9.5.2. Financial Performance
9.5.3. Product Benchmarking
9.5.4. Recent Development
9.6. Hologic, Inc.
9.6.1. Company Overview
9.6.2. Financial Performance
9.6.3. Product Benchmarking
9.6.4. Recent Development
9.7. Illimina, Inc.
9.7.1. Company Overview
9.7.2. Financial Performance
9.7.3. Product Benchmarking
9.7.4. Recent Development
9.8. Quest Diagnostics Incorporated
9.8.1. Company Overview
9.8.2. Financial Performance
9.8.3. Product Benchmarking
9.8.4. Recent Development
9.9. QuidelOrtho Corporation
9.9.1. Company Overview
9.9.2. Financial Performance
9.9.3. Product Benchmarking
9.9.4. Recent Development
9.10. Thermo Fisher Scientific Inc
9.10.1. Company Overview
9.10.2. Financial Performance
9.10.3. Product Benchmarking
9.10.4. Recent Development
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.